"Glucagon-Like Peptides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Peptides derived from proglucagon which is also the precursor of pancreatic GLUCAGON. Despite expression of proglucagon in multiple tissues, the major production site of glucagon-like peptides (GLPs) is the INTESTINAL L CELLS. GLPs include glucagon-like peptide 1, glucagon-like peptide 2, and the various truncated forms.
| Descriptor ID |
D004763
|
| MeSH Number(s) |
D06.472.317.469.500
|
| Concept/Terms |
Glucagon-Like Peptides- Glucagon-Like Peptides
- Glucagon Like Peptides
- Glucagon-Like Polypeptides
- Glucagon Like Polypeptides
|
Below are MeSH descriptors whose meaning is more general than "Glucagon-Like Peptides".
Below are MeSH descriptors whose meaning is more specific than "Glucagon-Like Peptides".
This graph shows the total number of publications written about "Glucagon-Like Peptides" by people in this website by year, and whether "Glucagon-Like Peptides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2020 | 1 | 0 | 1 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glucagon-Like Peptides" by people in Profiles.
-
Efficacy and Safety of GLP-1 Agonists on Metabolic Parameters in Non-diabetic Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2024 Dec; 69(12):4437-4445.
-
Semaglutide 2.4?mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial. Aliment Pharmacol Ther. 2024 Dec; 60(11-12):1525-1533.
-
Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression. Diabetes Obes Metab. 2024 Jun; 26(6):2209-2228.
-
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2023 08 31; 38(9):2041-2051.
-
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER. Circulation. 2022 02 22; 145(8):575-585.
-
Deficiency of glucagon gene-derived peptides induces peripheral polyneuropathy in mice. Biochem Biophys Res Commun. 2020 10 29; 532(1):47-53.
-
Noninsulin glucose-lowering agents for the treatment of patients on dialysis. Nat Rev Nephrol. 2013 Mar; 9(3):147-53.
-
Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia. 2004 May; 47(5):806-15.
-
RyR2 and calpain-10 delineate a novel apoptosis pathway in pancreatic islets. J Biol Chem. 2004 Jun 04; 279(23):24794-802.
-
Differential activation mechanisms of Erk-1/2 and p70(S6K) by glucose in pancreatic beta-cells. Diabetes. 2003 Apr; 52(4):974-83.